LTR Pharma, an ASX-listed company focused on men's health, has won the prestigious IPO of the Year Award, underscoring its entry into the public market.
The accolade presented by the Australian Stockbrokers Foundation in Sydney last week, highlighted Alpine Capital's role as lead manager for LTR Pharma's IPO, as instrumental in this achievement.
Since its IPO, LTR Pharma's stock surged 300% above its listing price of 20 cents, spurred by the news of positive initial Spontan results, with full trial outcomes expected in the coming months (PD 26 Mar).
LTR Pharma is dedicated to enhancing men's physical and mental health through the commercialisation of its nasal spray treatment for Erectile Dysfunction (ED) (PD 20 Feb).
ED affects millions of men worldwide, often leading to reduced self-esteem and strained personal relationships.
LTR Pharma's lead product, Spontan, offers a unique solution with its intranasal delivery of a PDE5 inhibitor.
The method facilitates rapid absorption allowing the drug to take effect within 10 minutes.
Phil Cawood, co-founder of Alpine Capital, said, "working with LTR Pharma on its IPO has been a rewarding experience".
"The company's commitment to innovation in men's health is truly inspiring, and we are proud to have played a role in their successful market entry.
"This recognition is well-deserved, and we anticipate a bright future for the company," said Cawood. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jun 24
